Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Epidermal growth factor receptor (EGFR) is a key oncogenic driver in various cancers.
• Existing therapies like tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) face limitations due to cancer heterogeneity and drug resistance.
• There is a critical need for novel therapeutic strategies to overcome resistance to anti-EGFR treatments.

Purpose of the Study:

• To review traditional and existing anti-EGFR therapies, including small molecule inhibitors, mAbs, and antibody-drug conjugates (ADCs).
• To highlight novel therapeutic modalities, focusing on molecular degraders such as PROTACs, LYTACs, AUTECs, and ATTECs.
• To discuss the design, synthesis, applications, and future opportunities of these emerging anti-EGFR agents.

Main Methods:

• Literature review and perspective synthesis.
• Analysis of existing anti-EGFR therapies and their limitations.
• Exploration of the mechanisms, design, and application of novel molecular degraders targeting EGFR.

Main Results:

• Traditional EGFR inhibitors (TKIs, mAbs, ADCs) have shown efficacy but are hampered by resistance mechanisms.
• Molecular degraders represent a promising new class of anti-EGFR therapeutics.
• Emerging modalities like PROTACs, LYTACs, AUTECs, and ATTECs demonstrate potential to overcome current treatment challenges.

Conclusions:

• Novel molecular degraders offer a promising avenue to overcome resistance in EGFR-targeted cancer therapy.
• Further research into the design, synthesis, and clinical application of these degraders is warranted.
• These advanced modalities hold significant potential for improving outcomes in EGFR-driven cancers.